CHANGES IN THE LOW-DENSITY-LIPOPROTEIN PROFILE DURING 17-BETA-ESTRADIOL DYDROGESTERONE THERAPY IN POSTMENOPAUSAL WOMEN

被引：40
|
作者：
VANDERMOOREN, MJ
DEGRAAF, J
DEMACKER, PNM
DEHAAN, AFJ
ROLLAND, R
机构：
[1] UNIV NIJMEGEN ST RADBOUD HOSP, DEPT OBSTET & GYNECOL, 6500 HB NIJMEGEN, NETHERLANDS
[2] UNIV NIJMEGEN ST RADBOUD HOSP, DEPT GEN INTERNAL MED, 6500 HB NIJMEGEN, NETHERLANDS
[3] UNIV NIJMEGEN ST RADBOUD HOSP, DEPT MED STAT, 6500 HB NIJMEGEN, NETHERLANDS
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 1994年 / 43卷 / 07期
关键词：
D O I：
10.1016/0026-0495(94)90256-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Changes in the low-density lipoprotein (LDL) subfractions, determined with gradient gel electrophoresis (GGE), were prospectively studied during hormone replacement therapy (HRT) in 23 healthy nonhysterectomized postmenopausal women. LDL subfractions were analyzed by densitometric scanning of the gels. We observed significant changes in the LDL subfraction profile toward a smaller particle size (P < .001). These changes could almost completely be attributed to the hormonal treatment regimen (P < .01), and may indicate an effect partially opposite to the other reported changes in the lipid profile. © 1994.
引用
收藏
页码：799 / 802
页数：4
相关论文
共 50 条
  • [31] Oral 17β-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women
    Pornel, B
    Chevallier, O
    Netelenbos, JC
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2002, 9 (03): : 171 - 178
  • [32] Influence of 17-beta-estradiol on cerebrovascular impedance during menstrual cycle in women
    Krejza, J
    Mariak, Z
    Nowacka, A
    Melhem, ER
    Babikian, VL
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2004, 221 (1-2) : 61 - 67
  • [33] BENEFICIAL-EFFECTS ON SERUM-LIPOPROTEINS BY 17-BETA-ESTRADIOL-DYDROGESTERONE THERAPY IN POSTMENOPAUSAL WOMEN - A PROSPECTIVE-STUDY
    VANDERMOOREN, MJ
    DEMACKER, PNM
    THOMAS, CMG
    ROLLAND, R
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1992, 47 (02): : 153 - 160
  • [34] Postprandial reduction in high-density lipoprotein cholesterol concentrations in postmenopausal women: Improvement by 17 beta-estradiol
    Westerveld, HT
    Meijer, E
    Erkelens, DW
    deBruin, TWA
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1996, 45 (07): : 827 - 832
  • [35] EFFECTS OF TRANSDERMAL 17-BETA-ESTRADIOL COMBINED WITH ORAL PROGESTOGEN ON LIPIDS AND LIPOPROTEINS IN HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN
    SLOWINSKASRZEDNICKA, J
    ZGLICZYNSKI, S
    CHOTKOWSKA, E
    SRZEDNICKI, M
    STOPINSKAGLUSZAK, U
    JESKE, W
    BRZEZINSKA, A
    ZGLICZYNSKI, W
    SADOWSKI, Z
    JOURNAL OF INTERNAL MEDICINE, 1993, 234 (05) : 447 - 451
  • [36] Acute effect of nasal pulsed 17-beta-estradiol in healthy and non-healthy postmenopausal women
    Clapauch, Ruth
    Uchoa, Helena B. M. P.
    Mattos, Tatiana M.
    Bonisson, Vinicius G.
    Ferreira, Andrea S. R.
    Lopes, Erika L.
    Nascimento, Isabel C. S.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (06): : 989 - 989
  • [37] DIFFERENTIAL-EFFECTS OF ESTROGEN ON LOW-DENSITY-LIPOPROTEIN SUBCLASSES IN HEALTHY POSTMENOPAUSAL WOMEN
    CAMPOS, H
    SACKS, FM
    WALSH, BW
    SCHIFF, I
    OHANESIAN, MA
    KRAUSS, RM
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (09): : 1153 - 1158
  • [38] Percutaneous 17 beta-estradiol replacement therapy in hypertensive postmenopausal women
    OsorioWender, MC
    Vitola, D
    Spritzer, PM
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 1997, 30 (09) : 1047 - 1053
  • [39] Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women
    Godsland, IF
    Manassiev, NA
    Felton, CV
    Proudler, AJ
    Crook, D
    Whitehead, MI
    Stevenson, JC
    CLINICAL ENDOCRINOLOGY, 2004, 60 (05) : 541 - 549
  • [40] Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations
    J-Ph. Devissaguet
    N. Brion
    O. Lhote
    P. Deloffre
    European Journal of Drug Metabolism and Pharmacokinetics, 1999, 24 : 265 - 271
12345